photoimmunotherapy

Twenty-four hours after the administration of the study drug, catheters are inserted into the tumor and lasers emitting a wavelength of light that activates the dye molecule on the ASP-1929 are illuminated.

October 14, 2021

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.

By Tom Wilemon